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Abstract
Background: The widespread use of tissue plasminogen activator (tPA), the only FDA-approved
acute stroke treatment, remains limited by its narrow therapeutic time window and related risks
of brain hemorrhage. Normobaric oxygen therapy (NBO) may be a useful physiological strategy
that slows down the process of cerebral infarction, thus potentially allowing for delayed or more
effective thrombolysis. In this study we investigated the effects of NBO started simultaneously with
intravenous tPA, in spontaneously hypertensive rats subjected to embolic middle cerebral artery
(MCA) stroke. After homologous clot injection, animals were randomized into different treatment
groups: saline injected at 1 hour; tPA at 1 hour; saline at 1 hour plus NBO; tPA at 1 hour plus NBO.
NBO was maintained for 3 hours. Infarct volume, brain swelling and hemorrhagic transformation
were quantified at 24 hours. Outcome assessments were blinded to therapy.
Results: Upon clot injection, cerebral perfusion in the MCA territory dropped below 20% of pre-
ischemic baselines. Both tPA-treated groups showed effective thrombolysis (perfusion restored to
nearly 100%) and smaller infarct volumes (379 ± 57 mm3 saline controls; 309 ± 58 mm3 NBO; 201
± 78 mm3 tPA; 138 ± 30 mm3 tPA plus NBO), showing that tPA-induced reperfusion salvages
ischemic tissue and that NBO does not significantly alter this neuroprotective effect. NBO had no
significant effect on hemorrhagic conversion, brain swelling, or mortality.
Conclusion: NBO can be safely co-administered with tPA. The efficacy of tPA thrombolysis is not
affected and there is no induction of brain hemorrhage or edema. These experimental results
require clinical confirmation.
Background
Intravenous tissue plasminogen activator (tPA) remains
the only acute stroke therapy that is approved by the FDA
and established to improve clinical outcome [1,2]. How-
ever, the use of this thrombolytic agent has been limited
by the need to deliver treatment within a narrow thera-
peutic time window, presently 3 hours, and the excess risk
of brain hemorrhage and edema ('reperfusion injury') if
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treatment is started at delayed time points after stroke
[1,2]. It is important to develop strategies that can safely
extend the therapeutic time window for tPA and thereby
increase the utilization of this effective treatment.
A key factor that increases the risks for brain edema and
hemorrhage, and reduces the efficacy of tPA, is the devel-
opment of substantial cellular necrosis prior to treatment.
Preventing early cell death may allow relatively delayed
thrombolysis with tPA, without compromising safety.
Several animal [3-16] and human [17-19] studies have
documented that normobaric oxygen therapy (NBO)
therapy is neuroprotective in acute ischemic stroke. Imag-
ing studies indicate that NBO slows down and transiently
arrests the process of ischemic cell death[6,14,18,19].
Since it is simple to administer, noninvasive, inexpensive,
widely available, and can be started in the field within
minutes after stroke symptom onset, NBO is being viewed
as a potentially useful and feasible physiological strategy
to extend the time window for stroke thrombolysis [20-
23].
In this study, we tested the hypothesis that NBO therapy
can be safely combined with tPA in an experimental clot-
based stroke model in rats. In order for combination NBO
plus tPA clinical trials to be initiated, one must first dem-
onstrate that NBO does not interfere with the efficacy or
compromise the safety of tPA thrombolysis. The experi-
mental design and results of this study are relevant to the
clinical scenario where tPA and NBO are started simulta-
neously upon hospital arrival.
Results
Physiological parameters remained within normal range
in all groups (Table 1). Before NBO, arterial pO2 levels
were approximately 120 mm Hg in all rats. As expected,
NBO rapidly and markedly elevated arterial pO2 levels to
above 400 mmHg (Table 1). Upon clot injection, cerebral
perfusion in the MCA territory dropped below 20% of
pre-ischemic baselines (Figure 1). Cerebral ischemia was
stable throughout the 3 hour duration of the study in all
animals (note that any animals showing spontaneous
recanalization were excluded; see Methods). tPA treat-
ment restored perfusion to almost 100%, but saline treat-
ment did not have detectable effects on cerebral perfusion
values (Figure 1). The addition of NBO did not affect the
rate or the time course of tPA-mediated reperfusion (Fig-
ure 1).
Table 1: Physiological Variables
Group
Saline + Air Saline + NBO t-PA + Air t-PA + NBO
Body Weight (g) 302.9 ± 8.1 304.0 ± 7.8 303.4 ± 6.6 306.3 ± 5.3
Rectal Temperture (°C)
before Air/NBO 37.0 ± 0.1 37.0 ± 0.1 37.0 ± 0.1 37.0 ± 0.1
30 min after Air/NBO 37.0 ± 0.1 37.0 ± 0.1 37.0 ± 0.1 37.0 ± 0.1
3 hr after Air/NBO 37.0 ± 0.1 37.0 ± 0.1 37.0 ± 0.1 37.0 ± 0.1
MABP (mmHg)
Before Air/NBO 182.9 ± 5.6 185.6 ± 5.6 185.9 ± 6.9 183.0 ± 5.1
30 min after Air/NBO 182.5 ± 7.1 187.4 ± 8.0 185.4 ± 8.1 185.6 ± 5.4
3 hr after Air/NBO 183.0 ± 6.3 186.1 ± 7.1 184.5 ± 6.3 182.1 ± 7.8
pH
Before Air/NBO 7.38 ± 0.01 7.37 ± 0.01 7.38 ± 0.01 7.38 ± 0.01
30 min after Air/NBO 7.38 ± 0.01 7.37 ± 0.01 7.38 ± 0.01 7.38 ± 0.01
3 hr after Air/NBO 7.38 ± 0.01 7.37 ± 0.01 7.37 ± 0.01 7.38 ± 0.01
pO2 (mmHg)
Before Air/NBO 121.8 ± 2.3 120.4 ± 5.0 119.8 ± 5.2 122.3 ± 6.5
30 min after Air/NBO 121.9 ± 2.7 434.9 ± 10.8 120.4 ± 4.6 434.0 ± 13.9
3 hr after Air/NBO 121.5 ± 3.7 443.1 ± 13.2 119.9 ± 5.2 438.7 ± 20.8
pCO2 (mmHg)
Before Air/NBO 45.3 ± 1.0 45.3 ± 1.6 45.9 ± 1.2 46.0 ± 1.4
30 min after Air/NBO 44.9 ± 0.8 44.6 ± 1.5 45.9 ± 1.5 45.7 ± 1.3
3 hr after Air/NBO 44.5 ± 1.2 45.3 ± 1.1 45.5 ± 1.3 45.1 ± 1.7
Values are mean ± SD. MABP indicates mean arterial blood pressure.BMC Neuroscience 2009, 10:79 http://www.biomedcentral.com/1471-2202/10/79
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This embolic clot model yielded infarctions in the
expected territory of the middle cerebral artery (Figure
2a). Treatment with NBO alone did not show a statisti-
cally significant decrease in infarction volume (309 ± 58
mm3 in NBO animals, 379 ± 57 mm3 in controls, Figure
2b). As expected, thrombolysis with tPA significantly
decreased infarction volumes (201 ± 78 mm3), consistent
with effective reperfusion. Combining NBO plus tPA did
not interfere with this beneficial action of tPA. In fact, the
average infarction volume of rats treated with NBO plus
tPA (138 ± 30 mm3) was even smaller than that in tPA-
alone rats (210 ± 78 mm3), although this difference was
not statistically significant (p = 0.26). Both tPA-treated
groups showed small cortical infarcts with subcortical tis-
sue salvage (Figure 2A), suggesting thrombolysis-induced
recanalization with distal clot migration or embolization,
as expected for this experimental model[24].
In Spontaneously Hypertensive rats (SHRs), this embolic
clot model demonstrates the presence of hemorrhagic
conversion if thrombolytic reperfusion occurs late, at 2–3
hours or beyond. In this study, tPA was given relatively
early, at 1 hour, which is the time point where reperfusion
occurs consistently in our experience. Accordingly, there
was no significant induction of hemorrhage. The calcu-
lated volumes of parenchymal blood were approximately
3–4 μL in all groups and neither NBO nor NBO plus tPA
appeared to worsen hemorrhage (Figure 3a). After correct-
ing for infarct volumes (Figure 3b), hemorrhage volume
tended to be higher in both tPA treated groups as com-
pared to saline controls (saline controls vs. tPA, p = 0.11,
and vs. tPA/NBO, p = 0.09).
Besides hemorrhagic conversion, another potential com-
plication of reperfusion injury is the induction of edema
and brain swelling. In this study, about 10% of hemi-
spheric swelling was observed in all animals. There were
no detectable differences across groups, and NBO did not
worsen brain swelling (Figure 3c). There was no signifi-
cant difference in mortality rates between groups (p =
0.73), indicating that NBO did not affect mortality when
Cerebral perfusion during embolic focal ischemia and reperfusion after tPA thrombolysis Figure 1
Cerebral perfusion during embolic focal ischemia and reperfusion after tPA thrombolysis. Cerebral perfusion as 
measured with laser Doppler flowmetry (mean ± SD) dropped rapidly below 20% after clot injection. Intravenous tPA therapy 
almost fully restored perfusion. Saline did not have detectable effects on cerebral perfusion values.BMC Neuroscience 2009, 10:79 http://www.biomedcentral.com/1471-2202/10/79
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administered alone or when combined with tPA (Table
2).
Discussion
Over the past few years, multiple studies have docu-
mented NBO's neuroprotective effects in hyperacute focal
ischemic stroke. Early NBO therapy salvages acutely
ischemic brain tissue, reduces pathological brain infarct
volumes, improves neurobehavioural scores, attenuates
diffusion-weighted brain MRI abnormalities, and extends
the reperfusion time window [3-16]. Pilot human studies
have shown similarly promising results [17-19]. Other
studies have shown that NBO does not induce post-
ischemic brain hemorrhage, brain edema, blood-brain
barrier damage, matrix metalloprotein levels, and various
other markers of oxidative stress[6,9,12,15]; these results
have helped to allay concerns about the potential risks of
hyperoxia-induced oxygen free radical generation. Finally,
several studies have shed light on mechanisms: NBO
raises brain tissue oxygen levels, reduces peri-infarct depo-
larizations that contribute to infarct growth, improves
MR-spectrophotometric parameters of ischemia e.g. brain
lactate levels, and favorably alters hemodynamic parame-
ters such as cerebral blood volume[8,11,13,14,18,19].
On basis of these data, and the inherent advantages of
NBO as an acute stroke therapy such as its wide availabil-
ity, ease of delivery in the field, and penetration across the
blood brain barrier to reach target ischemic brain tissue,
clinical trials of NBO have been initiated to determine
NBO's safety and therapeutic potential in the acute stroke
setting[17,18,25,26]. Combining NBO with tPA is a natu-
ral next step; however, before such trials can be initiated it
is important to investigate in pre-clinical studies whether
NBO influences the thrombolytic potency or the safety of
tPA. In that regard, the results of the present study are sig-
nificant. We found that the combination of NBO plus tPA
did not significantly alter the rate or the degree of tPA-
induced reperfusion as measured by LDF, and had no sig-
nificant effect on brain swelling or mortality. Both tPA-
treated groups showed significant reduction of infarct vol-
umes as compared to saline controls, and the combina-
tion of NBO with tPA proved most effective. The benefit
of combination therapy over tPA alone was marginal;
however, this study was not powered to show benefit of
combination therapy versus tPA. Both tPA groups showed
small residual cortical infarcts as expected for this embolic
clot-reperfusion stroke model[24]. NBO alone showed no
significant benefit, presumably because of the small sam-
ple size, because it was delivered at a relatively delayed
time frame (the therapeutic window in rodents is esti-
mated at between 30 and 45 minutes[14]), and because
LDF monitoring suggested non-reperfusion in the NBO-
only group (prior work suggests that NBO' immediate tis-
sue-salvaging effects cannot be sustained in the face of
prolonged hypoperfusion[6,14]). As with previous stud-
ies, it is important to note that NBO also did not worsen
infarct volume, showing lack of toxicity from mechanisms
such as increased oxygen free radical generation.
These data complement the results of prior studies show-
ing efficacy of NBO in mechanical models of reper-
Cerebral infarction volumes Figure 2
Cerebral infarction volumes. (a) Representative images of TTC staining are shown. (b) Effects of tPA and NBO on infarc-
tion volume at 24 hours. Intravenous tPA reduced infarct volumes but NBO did not alter this neuroprotective effect. Data 
expressed as mean ± SD; *$ P < 0.05.BMC Neuroscience 2009, 10:79 http://www.biomedcentral.com/1471-2202/10/79
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Effects of tPA and NBO on brain hemorrhage and brain swelling Figure 3
Effects of tPA and NBO on brain hemorrhage and brain swelling. Bar-graphs show the quantity of brain hemorrhage 
without (a) and with (b) correction for infarction volume, and (c) brain swelling at 24 hours. Intravenous tPA and NBO did not 
induce hemorrhagic conversion, and did not increase brain swelling.BMC Neuroscience 2009, 10:79 http://www.biomedcentral.com/1471-2202/10/79
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fusion[4-6,8-15]. Because of the inherent differences
between mechanical and thrombolytic approaches to
arterial recanalization, here we used a clinically relevant
stroke model of embolic MCA occlusion with tPA-
induced thrombolysis within a narrow therapeutic time
window. SHR rats were used since our main objective was
to determine safety; the incidence of tPA induced hemor-
rhage is higher in SHR rats. Moreover, SHR rats develop
more reproducible infarcts, which is an important consid-
eration given that infarct size is more variable with the
embolic clot model than with the filament model.
Our results are most applicable to the clinical setting
where patients receive intravenous tPA and NBO simulta-
neously  after hospital arrival. A previous rodent study
modeling the clinical scenario where NBO is started in the
field, followed by delayed tPA administration, has shown
similarly promising results[7]. In that study, NBO was
started at 30 minutes and tPA was administered at 3 hours
after embolic MCA occlusion. Serial diffusion-perfusion
magnetic resonance imaging (MRI) showed that the com-
bination of NBO with tPA was effective (reduced the
growth of diffusion-MRI lesions, smaller pathological inf-
arct volumes) and also safe (no increase in the rate or the
volume of brain hemorrhage). If confirmed in clinical tri-
als, these data may result in the widespread use of NBO as
an adjunctive stroke treatment strategy that extends the
time window for intravenous tPA. NBO may eventually
also have a role in extending the therapeutic time window
for other promising treatments including intra-arterial
thrombolytics and neuroprotective drugs, which to date
have failed clinical trials due to factors such as delayed
time to treatment, among others [27,28].
The strengths of our study include the blinded assessment
of outcomes, careful monitoring of physiological parame-
ters and cerebral perfusion, statistical rigor, and the clini-
cally relevant study design. These factors are often
overlooked in pre-clinical studies [29,30]. We acknowl-
edge several shortcomings, for example the absence of
neurobehavioural scores and investigation of mecha-
nisms. These issues have been addressed in prior studies;
our objective was to investigate the interaction between
NBO and intravenous tPA. Further studies are warranted
to investigate issues such as the effect of varying durations,
timings, and concentrations of inhaled oxygen, and intra-
venous tPA's therapeutic time window with NBO pre-
treatment and co-treatment. Nevertheless, we hope that
our results will lend confidence to starting clinical investi-
gations of NBO with tPA.
Conclusion
These experimental results suggest that NBO can be safely
co-administered with intravenous tPA to treat acute
ischemic stroke. The efficacy of tPA thrombolysis is not
affected by NBO, and there is no induction of brain hem-
orrhage or brain edema.
Methods
Animal Model
All experiments were performed under Protocol No.
2006N000138 approved by the Massachusetts General
Hospital Subcommittee on Research Animal Care, and in
accordance with the internationally recognized National
Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals. Spontaneously hypertensive male
rats (Charles River Laboratories, Wilmington, MA) were
anesthetized with isoflurane (5% induction, 1–1.2%
maintenance) in a 30% oxygen and 70% nitrous oxide
mix. Temperature was maintained at 37 ± 0.5°C with a
heating pad. Right femoral arteries were cannulated to
monitor pressure, pH and gases. The embolic stroke
model was adapted from Zhang, et al.[31] Briefly, 3 cm of
homologous clots were injected via a modified PE-50
catheter to occlude the middle cerebral artery (MCA).
After embolization, animals were randomly allocated to
one of four treatment groups: intravenous saline injected
at 1 hour after ischemia; intravenous tPA injected at 1
hour after ischemia; saline injected at 1 hour after
ischemia plus NBO; tPA injected at 1 hour after ischemia
plus NBO.
Consistent with STAIR recommendations[29], the experi-
ment was performed in blinded fashion, as follows. Ran-
domization was performed after embolization in order to
confirm successful clot placement and drop in laser Dop-
pler flowmetry (LDF) values. The investigator performing
the surgery (YM) left the room after clot placement. A sec-
ond 'unblinded' investigator (NF or KA) performed the
randomization, administered the intravenous solution,
manipulated gas flow rates, obtained arterial blood gases,
and adjusted the anesthesia or flow of gas if warranted.
The room air and oxygen flowmeters were covered in
order to protect the blind. The blinded investigator (YM)
then returned to complete the surgical procedure and
monitor HR, BP, and LDF during the period of anesthesia,
but did not view potentially unblinding information such
as flow of gas or arterial blood gas results. A separate set of
blinded investigators (JL, YE) and the blinded surgeon
(YM) assessed outcomes at 24 hours. If the animal died
Table 2: Mortality Rates
Group salile+Air saline+NBO tPA+Air tPA+NBO
n = 11 n = 9 n = 14 n = 10
dead 3 2 6 3
mortality rate 27% 22% 43% 30%BMC Neuroscience 2009, 10:79 http://www.biomedcentral.com/1471-2202/10/79
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before the 24-hour time point, the unblinded investiga-
tors (NF, KA) were informed and the number of animals
in that group adjusted accordingly.
Intravenous tPA (Genentech, San Francisco, CA) was
administered at 10 mg/kg with a 10% bolus and 90% con-
tinuous infusion over 30 minutes. LDF probes placed 2
mm posterior and 5 mm lateral to the bregma were used
to monitor cerebral perfusion. Only rats that showed sus-
tained ischemia to less than 20% of pre-ischemic base-
lines until the time of injection were included. Animals
with LDF value changes suggesting spontaneous recanali-
zation before saline or tPA injection were excluded. All
gases were delivered via a simple face mask to free-breath-
ing animals. NBO was achieved by stopping nitrous oxide
and increasing the concentration of oxygen to 100%.
NBO was started simultaneously with saline or tPA injec-
tion (at 1 hour) and continued for a duration of 3 hours.
At 4 hours after MCA occlusion (3 hours after saline or tPA
injection), anesthesia was discontinued and rats were
returned to their cages.
Measurement of Infarction, Brain swelling and Intracranial 
Hemorrhage
All rats were sacrificed at 24 hours after ischemia under
deep pentobarbital anesthesia, brains were transcardially
perfused with saline, and seven coronal sections (2 mm
thick) were stained with 2,3,5-triphenyltetrazolium chlo-
ride (TTC; Sigma, St. Louis, MO) to quantify infarct vol-
umes as described previously [14,15]. The degree of brain
swelling was estimated as the volumetric ratio of the
ischemic side divided by the contra-lateral side. Cerebral
hemorrhage was measured using a spectrophotometric
assay to quantify hemoglobin in perfused brain[15]. We
have previously shown that hemoglobin measurements
can be simultaneously performed on TTC-stained sec-
tions[32].
Statistical Methods
Power and sample size calculations, based on the
expected size and standard deviation for infarct volumes
in prior experiments and the anticipated effect size for tPA
versus saline controls, suggested that 7 to 8 animals per
group would be required to achieve statistical signifi-
cance. Accordingly, the surgical experiments were contin-
ued until we reached at least 7 rats per group that survived
until 24 hours and were not initially excluded due to
spontaneous recanalization. Continuous variables (phys-
iological parameters, LDF values, and infarction, brain
edema, and hemorrhage volumes) were analyzed with
ANOVA followed by Tukey-Kramer tests. Mortality rates
were compared using the Chi-square test. Differences with
P < 0.05 were considered statistically significant. Data are
expressed as mean ± SD.
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